Key facts
- Notable investors include Green Pine Capital Partners, Jiuzhi Capital, Beijing Energy Tongxin Investment, Beijing Innovation Industry Investment.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Wiseheart Medval
- ·The full record, as it builds
Funding rounds
No funding rounds for Wiseheart Medval are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Wiseheart Medval
Developer of drugs designed for cell therapy for neurological diseases. The company uses somatic cell reprogramming technology and non-integrated system to directly induce neural stem cells (iNSCs) from human peripheral blood mononuclear cells or fibroblasts, and can efficiently differentiate into specific nerve cells, providing patients who have Parkinson's disease and other neurological diseases with effective drugs.
- Sector
- Healthcare
- HQ
- Beijing, China
- Founded
- 2021
- Website
- wiseheartmed.com/
- Ownership
- Privately Held (backing)
Wiseheart Medval doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Wiseheart Medval shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Wiseheart Medval in its N-PORT filings yet. We sweep new filings monthly.